|
Innovation Fails Because of Corporate Antibodies
Innovation Excellence (blog) Innovation Fails Because of Corporate Antibodies Here’s a big reason why open innovation efforts can fail: they are often killed by corporate antibodies resisting the changes brought by opening up to external partners. These antibodies can exist in … |
Bulls vs. Bears: Can Biogen Keep Booming?Investorplace.comLast week, BIIB announced positive phase 2 clinical trial results for its developmental MS drug daclizumab, noting that it significantly reduced brain lesions in patients with the relapsing-remi…
Common variable immunodeficiency unmasked by treatment of immune …7thSpace Interactive (press release)To our knowledge this is the first report of development of CVID in a patient with normal immunoglobulin prior to Rituximab treatment.Case presentat…
Combo Tx Gets Perfect Score in LymphomaMedPage TodayWASHINGTON — A three-drug combination — vorinostat (Zolinza), cladribine, and rituximab (Rituxan) — led to a 100% response rate in a small study of patients with advanced mantle cell lymphoma. All …
|
NIH trial shows promising results in treating a lymphoma in young people
National Institutes of Health (press release) Wyndham Wilson, M.D., Ph.D., head of NCI’s Lymphoma Therapeutics Section, and colleagues conducted the trial, in which every patient received the drugs etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone, and rituximab in a regimen … |
|
Draft NICE Guidance for Aggressive non-Hodgkin Lymphoma Treatment …
Sacramento Bee The European Medicines Agency’s (the EMA) Committee for Medicinal Products for Human Use has accepted PIX306, CTI’s ongoing randomized controlled Phase 3 clinical trial, which compares PIXUVRI-rituximab to gemcitabine-rituximab in patients who … |
 ABC News |
Tamiflu sales boost Roche results despite efficacy concerns
PMLiVE … but there were solid gains for the firm’s blockbuster cancer drugs, with Herceptin (trastuzumab) and Avastin (bevacizumab) both rising 11 per cent to 1.57bn Swiss francs and 1.53bn Swiss francs respectively, and MabThera/Rituxan (rituximab) up 6 … Roche sales rise thanks to oncology drugs and TamifluPharmaTimes Roche 1st-qtr 2013 sales grow 6%, driven by cancer drugsThe Pharma Letter |
Draft NICE Guidance for Aggressive non-Hodgkin Lymphoma Treatment …PR Newswire (press release)CTI is currently accruing patients into a Phase 3 trial comparing PIXUVRI and rituximab with gemcitabine and rituximab in the setting of aggressive B-cell N…
Rituximab may obviate radiation in mediastinal B-cell lymphomaThe Oncology ReportPatients in a single-group, prospective phase II study were treated with dose-adjusted etoposide, doxorubicin, cyclophosphamide with vincristine, prednisone, and rituximab…
|
Rituxan Lymphoma Tx Works Without Radiation
MedPage Today A dose-adjusted, infusion approach to aggressive chemotherapy with rituximab (Rituxan) may allow patients with primary mediastinal B-cell lymphoma to skip radiation, a small uncontrolled trial suggested. Among 51 such treated patients, 97% survived and … New Strategy Helps Young Lymphoma Patients Avoid Radiation TreatmentU.S. News & World Report |